Adaptive Biotechnologies (ADPT) vs CRISPR Therapeutics (CRSP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adaptive Biotechnologies (ADPT) has outperformed CRISPR Therapeutics (CRSP) over the past year, gaining 83.1% versus a loss of 25.9%. Over five years, ADPT leads with a -21.6% price change compared with -46.0% for CRSP. CRISPR Therapeutics is the larger company by market cap ($4.97 billion vs $4.10 billion), about 1.2 times the size, while Adaptive Biotechnologies is growing revenue faster (+54.8% vs -90.6%).
Adaptive Biotechnologies converts more of its revenue into profit, with a net margin of -21.5% versus -16569.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADPT | CRSP |
|---|---|---|
| Share price | $25.69 | $51.37 |
| Market cap | $4.10B | $4.97B |
| 1-day change | -2.25% | -1.87% |
| YTD return | +61.82% | -0.17% |
| 1-year return | +83.14% | -25.87% |
| 5-year return | -21.55% | -46.03% |
| EPS (TTM) | $-0.41 | $-4.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $276.98M | $3.51M |
| Revenue growth (YoY) | +54.77% | -90.59% |
| Net income (latest FY) | $-59.50M | $-581.60M |
| Gross margin | 74.24% | — |
| Operating margin | -20.62% | -18933.65% |
| Net margin | -21.48% | -16569.77% |
| 52-week high | $30.74 | $78.38 |
| 52-week low | $12.00 | $44.12 |
| Distance from 52-week high | -16.43% | -34.46% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +10.20% | +70.45% |
| Average volume | 2.38M | 1.59M |
| Shares outstanding | 159.60M | 96.69M |
| Employees | 624 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADPT has outperformed CRSP by 109.0 percentage points over the past year.
- Adaptive Biotechnologies is more profitable, keeping -21.5 cents of every revenue dollar as net income versus -16569.8 cents for CRISPR Therapeutics.
- Adaptive Biotechnologies grew revenue faster in its latest fiscal year (+54.77% vs -90.59%).
About Adaptive Biotechnologies
ADPT stock →Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 624 employees
About CRISPR Therapeutics
CRSP stock →CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
ADPT vs CRSP FAQ
Which is bigger, Adaptive Biotechnologies or CRISPR Therapeutics?
CRISPR Therapeutics (CRSP) is larger, with a market capitalization of $4.97B compared with $4.10B for Adaptive Biotechnologies (ADPT).
Which stock has performed better over the past year, ADPT or CRSP?
ADPT returned +83.14% over the past 12 months, compared with -25.87% for CRSP (price return, excluding dividends). Past performance does not predict future results.
Are Adaptive Biotechnologies and CRISPR Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.